![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/7/74/Idelalisib.svg/640px-Idelalisib.svg.png&w=640&q=50)
Idelalisib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about idelalisib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.[5][4] Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[7][8] It was developed by Gilead Sciences. It is taken orally (swallowed by mouth).
Quick Facts Clinical data, Pronunciation ...
![]() Idelalisib structure | |
Clinical data | |
---|---|
Pronunciation | /aɪˈdɛləlɪsɪb/ eye-DEL-ə-li-sib |
Trade names | Zydelig |
Other names | GS-1101, CAL-101 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614040 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >84%[5] |
Metabolism | Aldehyde oxidase (~70%), CYP3A4 (~30%);[6] UGT1A4 (minor) |
Metabolites | GS-563117 (inactive in vitro) |
Onset of action | Tmax = 1.5 hours |
Elimination half-life | 8.2 hours |
Excretion | Feces (78%), urine (14%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.235.089 ![]() |
Chemical and physical data | |
Formula | C22H18FN7O |
Molar mass | 415.432 g·mol−1 |
3D model (JSmol) | |
| |
|
Close